TD Cowen raised the firm’s price target on TransMedics (TMDX) to $130 from $120 and keeps a Buy rating on the shares. The firm notes the company sailed past Q1 estimates and raised its 2025 revenue guidance by $34M. This strong performance should defuse recent dire predictions from a short-seller, TD Cowen says. On the call, TransMedics expressed confidence that it will deliver on its now higher guidance. Continued operating strength, along with progress with the next-gen programs in lung and heart, should further dent the bear thesis and help the stock, it adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target raised to $130 from $125 at Oppenheimer
- TransMedics price target raised to $125 from $105 at Piper Sandler
- TransMedics Group: Balancing Strong Q1 Performance with Growth and Margin Concerns
- TransMedics Group: Strong Performance with Cautious Outlook Amid Competitive and Reimbursement Uncertainties
- TransMedics Reports Strong Q1 2025 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue